Analyzing Biomerica (NASDAQ:BMRA) & Anteris Technologies Global (NASDAQ:AVR)

Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and Biomerica (NASDAQ:BMRA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Insider & Institutional Ownership

22.3% of Biomerica shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by company insiders. Comparatively, 12.3% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Anteris Technologies Global has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Valuation & Earnings

This table compares Anteris Technologies Global and Biomerica”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anteris Technologies Global $2.33 million 238.30 -$94.14 million ($1.61) -3.54
Biomerica $4.45 million 0.92 -$3.78 million ($1.64) -0.80

Biomerica has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Anteris Technologies Global and Biomerica’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anteris Technologies Global -4,637.48% -57.15% -50.73%
Biomerica -115.50% -142.81% -77.83%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Anteris Technologies Global and Biomerica, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anteris Technologies Global 1 1 3 0 2.40
Biomerica 1 0 0 0 1.00

Anteris Technologies Global currently has a consensus target price of $13.75, suggesting a potential upside of 141.23%. Biomerica has a consensus target price of $9.00, suggesting a potential upside of 581.82%. Given Biomerica’s higher possible upside, analysts clearly believe Biomerica is more favorable than Anteris Technologies Global.

About Anteris Technologies Global

(Get Free Report)

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.

About Biomerica

(Get Free Report)

Biomerica, Inc. is a medical diagnostic company that develops, manufactures and markets in vitro diagnostic products. Its tests are designed to help detect and assess a range of health conditions, with a focus on gastrointestinal disorders, food sensitivities and related areas. The company’s offerings include laboratory-based and point-of-care tests, including its inFoods IBS blood test, which is intended to help guide dietary management for people with irritable bowel syndrome. Biomerica also sells diagnostic products for other applications, including infectious and inflammatory conditions.

Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.